<?xml version="1.0" encoding="UTF-8"?>
<p>In summary, the exclusion of HIV-infected patients from oncology ICI trials appears to be neither supported by evidence from basic research nor early clinical trials. On the contrary, many lines of evidence suggest that ICI could be employed to improve HIV-specific immunity and thus contribute to HIV remission or even possible cure strategies.
 <xref rid="R23" ref-type="bibr">23 26 27</xref> However, the mechanisms regulating HIV persistence are complex and not yet fully understood, leading to the hypothesis that a combined treatment approach including ICI and cytokines will be required to accomplish such complete remissions.
 <xref rid="R28" ref-type="bibr">28</xref>
</p>
